Your browser is no longer supported. Please, upgrade your browser.
Radius Health, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own16.20% Shs Outstand46.65M Perf Week0.27%
Market Cap888.69M Forward P/E33.10 EPS next Y0.56 Insider Trans6.90% Shs Float46.46M Perf Month-0.16%
Income-112.50M PEG- EPS next Q-0.32 Inst Own- Short Float12.17% Perf Quarter16.11%
Sales231.50M P/S3.84 EPS this Y18.70% Inst Trans1.29% Short Ratio12.48 Perf Half Y55.32%
Book/sh-2.65 P/B- EPS next Y175.70% ROA-57.20% Target Price22.71 Perf Year-7.80%
Cash/sh2.41 P/C7.75 EPS next 5Y29.60% ROE105.10% 52W Range10.15 - 23.84 Perf YTD4.54%
Dividend- P/FCF- EPS past 5Y1.70% ROI-71.70% 52W High-19.51% Beta0.93
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin92.60% 52W Low89.04% ATR1.27
Employees310 Current Ratio2.50 Sales Q/Q12.70% Oper. Margin-35.60% RSI (14)46.81 Volatility6.45% 6.58%
OptionableYes Debt/Eq- EPS Q/Q14.40% Profit Margin-47.20% Rel Volume2.41 Prev Close18.67
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume452.74K Price19.19
Recom2.60 SMA20-4.74% SMA50-4.92% SMA20027.97% Volume1,091,997 Change2.79%
Feb-24-21Reiterated H.C. Wainwright Neutral $22 → $25
Sep-29-20Resumed JP Morgan Neutral $23
Jul-08-20Downgrade SVB Leerink Outperform → Mkt Perform $17
May-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $20
Apr-24-20Initiated Stifel Hold $20
Aug-29-19Upgrade Citigroup Neutral → Buy $24 → $40
May-30-19Resumed Citigroup Neutral
May-29-19Upgrade Goldman Neutral → Buy
Feb-14-19Initiated H.C. Wainwright Neutral $22
Mar-29-18Initiated Leerink Partners Outperform $53
Jan-29-18Initiated Morgan Stanley Overweight $57
Dec-06-17Initiated Citigroup Neutral $30
Oct-06-17Resumed Goldman Neutral
Mar-24-17Reiterated H.C. Wainwright Buy $71 → $66
Sep-21-16Reiterated H.C. Wainwright Buy $55 → $71
Aug-04-16Downgrade Maxim Group Hold → Sell $24
May-23-16Initiated H.C. Wainwright Buy $55
Mar-30-16Initiated Goldman Neutral
Feb-24-16Downgrade Jefferies Buy → Hold
Oct-02-15Initiated JP Morgan Overweight $88
Mar-03-21 04:15PM  
Feb-26-21 12:08PM  
Feb-25-21 05:01PM  
Feb-17-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 12:33PM  
Feb-09-21 09:29AM  
Jan-25-21 10:34AM  
Jan-07-21 11:05AM  
Jan-06-21 12:00PM  
Jan-05-21 08:36AM  
Jan-04-21 04:30PM  
Dec-18-20 09:30PM  
Dec-15-20 09:00AM  
Dec-05-20 11:32AM  
Nov-09-20 10:21AM  
Nov-05-20 10:32PM  
Oct-29-20 12:35PM  
Oct-21-20 08:15AM  
Oct-20-20 04:15PM  
Oct-06-20 04:30PM  
Oct-05-20 12:46PM  
Oct-01-20 08:45AM  
Sep-25-20 06:15AM  
Sep-24-20 04:15PM  
Sep-09-20 11:30AM  
Sep-08-20 08:00AM  
Sep-02-20 04:15PM  
Aug-25-20 09:00AM  
Aug-10-20 09:01PM  
Aug-03-20 12:31PM  
Jul-27-20 04:15PM  
Jul-24-20 07:15AM  
Jul-23-20 04:15PM  
Jul-17-20 10:54AM  
Jun-16-20 10:44AM  
Jun-10-20 05:07PM  
Jun-06-20 11:31AM  
May-27-20 05:00AM  
May-08-20 04:46PM  
May-07-20 04:15PM  
Apr-30-20 12:34PM  
Apr-28-20 04:35PM  
Apr-20-20 04:15PM  
Apr-08-20 12:13PM  
Mar-28-20 11:30AM  
Mar-03-20 09:15AM  
Mar-02-20 07:47AM  
Feb-27-20 09:05AM  
Feb-26-20 08:36AM  
Feb-25-20 11:28AM  
Feb-20-20 12:31PM  
Feb-13-20 04:05PM  
Jan-22-20 06:36AM  
Jan-13-20 09:00AM  
Jan-09-20 01:30PM  
Jan-06-20 04:14PM  
Dec-12-19 09:36AM  
Dec-10-19 03:38PM  
Dec-06-19 09:47AM  
Dec-05-19 11:31AM  
Dec-02-19 04:52PM  
Nov-15-19 04:15PM  
Nov-09-19 10:21AM  
Nov-06-19 11:10AM  
Nov-05-19 08:05PM  
Oct-29-19 10:33AM  
Oct-27-19 06:42PM  
Oct-24-19 04:34AM  
Oct-23-19 05:37PM  
Sep-13-19 06:03PM  
Sep-09-19 10:48AM  
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grausso SalChief Commercial OfficerFeb 25Sale18.931,32225,02511,709Feb 26 04:36 PM
BIOTECH TARGET N V10% OwnerNov 05Buy14.26100,0001,426,2307,455,714Nov 09 11:29 AM
BIOTECH TARGET N V10% OwnerSep 14Buy11.69200,0002,338,6807,355,714Sep 16 12:01 PM
BIOTECH TARGET N V10% OwnerSep 11Buy11.33199,0292,255,1187,155,714Sep 14 04:03 PM
BIOTECH TARGET N V10% OwnerJul 08Buy13.2125,000330,1786,956,685Jul 09 02:40 PM
BIOTECH TARGET N V10% OwnerApr 30Buy15.7550,000787,5556,931,685May 04 05:32 PM